The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellular carcinoma after liver transplantation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGtumor recurrence and metastasis
Examination of tumor recurrence include serum levels of alpha-fetoprotein(AFP), chest radiography, abdominal ultrasonography, chest or abdominal computed tomography (CT), magnetic resonance imaging (MRI) and bone scintigraphy
Time frame: within the first year after liver transplantation
Postoperative survival
Postoperative survival include rates of disease-free survival (DFS), overall survival(OS), tumor recurrence and death.
Time frame: within the first year after liver transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.